Fangyan Dai

Fangyan Dai

Auto-generated profile, based on publicly available information

Fangyan Dai

Hematologics, Inc., Seattle, Washington

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2025 in Blood Cancer Discovery
Verified
Journal Article
Closed access
CLCurtis Lachowiez
Curtis Lachowiez
MHMael Heiblig
Mael Heiblig
GRGaspar Aspas Requena
Gaspar Aspas Requena
ETEmmanuelle Tavernier-Tardy
Emmanuelle Tavernier-Tardy
FDFangyan Dai
Fangyan Dai
DPDaniel A. Pollyea
Daniel A. Pollyea
Resistance to venetoclax (VEN)-based therapy in acute myeloid leukemia (AML) includes genetic (i.e., mutations in N/KRAS, FLT3-ITD, TP53) and phenotypic (i.e., monocytic differentiation) features. Whether monocytic differentiation contributes to clinical VEN resistance secondary to a genetic bias remains unknown. This multimodal, multicenter, international analysis, inclusive of 678 patients, comprehensively characterized the prognostic role of monocytic differentiation in patients with AML treated with hypomethylating agents combined with VEN. AML genetics and monocytic differentiation (HR = 1.89; 95% confidence interval, 1.35–2.66; P < 0.001) in NPM1 wild-type cases correlated with an increased risk of death, clustering of centralized quantitative multiparameter flow cytometry data, evaluation of RNA sequencing-derived AML maturation stage, and single-cell proteogenomics linked driver mutations with AML phenotype and antiapoptotic gene expression. This comprehensive analysis of AML genetics, phenotype, and antiapoptotic protein expression highlights the complementary role these factors impart following VEN-based therapy. Significance: AML with monocytic differentiation often occurs in the context of co-occurring mutations within signaling pathways. In certain AML subgroups (such as NPM1 wild-type and signaling pathway gene–mutated), a monocytic phenotype is associated with decreased overall survival following VEN-based therapy. See related commentary by Renders, p. 403

1 December 2000 in Genomics
Verified
Journal Article
Closed access
PZPingzhao Zhang
Pingzhao Zhang
LYLong Yu
Long Yu
JGJie Gao
Jie Gao
QFQiang Fu
Qiang Fu
FDFangyan Dai
Fangyan Dai
SZShouyuan Zhao
Shouyuan Zhao

1 July 2008 in Developmental Cell
Verified
Journal Article
Closed access
KWKatharine H. Wrighton
Katharine H. Wrighton
FDFangyan Dai
Fangyan Dai
XFXin-Hua Feng
Xin-Hua Feng

10 May 2010
Verified
Book Chapter
Open access
PDF file
FDFangyan Dai
Fangyan Dai
XDXueyan Duan
Xueyan Duan
YLYao-Yun Liang
Yao-Yun Liang
LXlin xia
lin xia
XFXin-Hua Feng
Xin-Hua Feng
In eukaryotes, regulation of signaling mediators/effectors in the nucleus is one of the principal mechanisms that govern duration and strength of signaling. Smads are a family of structurally related intracellular proteins that serve as signaling effectors for transforming growth factor beta (TGF-β) and TGF-β-related proteins. Accumulating evidence demonstrates that Smads possess intrinsic nucleocytoplasmic shuttling capacity, which enables them to transmit TGF-β signals from cell membrane to nucleus. We recently identified two important steps in the termination of nuclear Smad signaling. The first step is initiated by a serine/threonine phosphatase PPM1A that dephosphorylates Smad2/3 in the nucleus, thereby shutting down signaling capacity of phosphorylated Smad2/3. The second step involves nuclear export of dephosphorylated Smad2/3 with the aid of nuclear protein RanBP3 to terminate Smad signaling. This chapter introduces methods for examining nuclear export of Smad2/3 in TGF-β signaling.

3 September 2025
Verified
Other
Open access
PDF file
CLCurtis Lachowiez
Curtis Lachowiez
MHMael Heiblig
Mael Heiblig
GRGaspar Aspas Requena
Gaspar Aspas Requena
ETEmmanuelle Tavernier-Tardy
Emmanuelle Tavernier-Tardy
FDFangyan Dai
Fangyan Dai
DPDaniel A. Pollyea
Daniel A. Pollyea
Overview of immunophenotypic expression profiling. (A) Flow cytometry was performed on diagnostic bone marrow specimens and fluorescence measurements, forward light scatter (FSC) and right-angle light scatter (SSC) characteristics were collected for 200,000 events. Leukemic populations were identified by CD45 v SSC gating, and, in a small subset of cases with markedly hypogranular myeloids, by CD34 gate (these cases all contained an entirely CD34 positive blast population). Final gating for every case was reviewed by a pathologist. (B) For cells identified in the leukemia gate, the mean intensity for each parameter (represented by a black dot) was computed.

3 September 2025
Verified
Other
Open access
PDF file
CLCurtis Lachowiez
Curtis Lachowiez
MHMael Heiblig
Mael Heiblig
GRGaspar Aspas Requena
Gaspar Aspas Requena
ETEmmanuelle Tavernier-Tardy
Emmanuelle Tavernier-Tardy
FDFangyan Dai
Fangyan Dai
DPDaniel A. Pollyea
Daniel A. Pollyea
RNA expression of alternative anti-apoptotic proteins based on RNA-seq defined cell differentiation state. Samples from the top quartile of each state are displayed below.